Publication date: Jan 30, 2025
The endTB trial is one of four recent efforts to use randomized controlled trials to test new, shorter, less toxic regimens for drug-resistant TB. For many years, the only approved treatment regimens lasted years and included daily injections and highly toxic medications with often-severe side effects. The three successful new regimens were successful for between 85 and 90% of patients, compared with 81% success for people in the control group. endTB uses two new drugs, bedaquiline and delamanid, which-when brought to market in 2012-2013-were the first new TB medicines developed in nearly 50 years. “This Harvard-led partnership among NGOs, ministries of health, and other academic partners identified three new regimens that will make lifesaving care dramatically more accessible,” Mitnick said. All of these innovations together mean the new shortened, all-oral regimens are available to more people than ever. The goal was to improve treatment for patients with tuberculosis resistant to rifampin.
| Concepts | Keywords |
|---|---|
| Antibiotics | Clinical |
| Killers | Drug |
| Peru | Drugs |
| Effective | |
| Endtb | |
| Included | |
| Regimens | |
| Resistant | |
| Tb | |
| Treat | |
| Treatment | |
| Trial | |
| Trials | |
| Tuberculosis | |
| Years |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | quality |
| drug | DRUGBANK | Medrysone |
| pathway | KEGG | Hepatitis C |
| disease | MESH | hepatitis C |
| drug | DRUGBANK | Spinosad |
| disease | MESH | emergency |
| drug | DRUGBANK | Pretomanid |
| drug | DRUGBANK | Delamanid |
| drug | DRUGBANK | Bedaquiline |
| drug | DRUGBANK | Rifampicin |
| pathway | REACTOME | Infectious disease |
| disease | MESH | infectious disease |
| pathway | KEGG | Tuberculosis |
| disease | MESH | Tuberculosis |
| disease | MESH | drug-resistant tuberculosis |